(Q35692031)

9 August 2017

1 reference

title

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy (English)

1 reference

9 August 2017

1 reference

Sergio Fazio

1

1 reference

9 August 2017

MacRae F Linton

series ordinal

2

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Current Atherosclerosis Reports

9 August 2017

published in

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

148-157

1 reference

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-004-0104-8

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators

21 January 2018

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

1 reference

12 December 2020

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

12 December 2020

Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management

1 reference

12 December 2020

Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner

1 reference

12 December 2020

Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia

1 reference

12 December 2020

Learning from the cerivastatin experience

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages

1 reference

12 December 2020

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

1 reference

12 December 2020

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

12 December 2020

Drug treatment of lipid disorders

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment

1 reference

12 December 2020

Statin-fibrate combination therapy

1 reference

12 December 2020

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

1 reference

12 December 2020

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

1 reference

12 December 2020

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response

1 reference

12 December 2020

Pharmacology of fenofibrate

1 reference

12 December 2020

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia

1 reference

12 December 2020

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

12 December 2020

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

1 reference

12 December 2020

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

12 December 2020

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Role of fibrates in the management of hypertriglyceridemia

1 reference

12 December 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

12 December 2020

Gemfibrozil Reduces Plasma C-Reactive Protein Levels in Abdominally Obese Men With the Atherogenic Dyslipidemia of the Metabolic Syndrome

1 reference

12 December 2020

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

1 reference

12 December 2020

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

12 December 2020

Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

The PPARalpha-leukotriene B4 pathway to inflammation control.

1 reference

12 December 2020

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

1 reference

12 December 2020

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

1 reference

12 December 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

12 December 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Effects of fibrates on metabolism of statins in human hepatocytes

1 reference

12 December 2020

Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Combination therapy for combined dyslipidemia

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Cardiovascular risks: New insights from Framingham

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Regulation of apo A-I gene expression by fibrates

1 reference

12 December 2020

Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

12 December 2020

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout

1 reference

12 December 2020

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

12 December 2020

Management of dyslipidemia in adults with diabetes

1 reference

12 December 2020

Hypertriglyceridemia as a cardiovascular risk factor

1 reference

12 December 2020

Statin-associated myopathy

1 reference

12 December 2020

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

1 reference

12 December 2020

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

12 December 2020

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

12 December 2020

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

12 December 2020

Combination therapy for dyslipidemia: safety and regulatory considerations

1 reference

12 December 2020

10.1007/S11883-004-0104-8

Identifiers

DOI

1 reference

9 August 2017

1 reference